Übersichtsarbeit
Spironolactone for acne in women
Drug and Therapeutics Bulletin · 2023
DOI: 10.1136/dtb.2023.000040 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug and Therapeutics Bulletin, 2023. Hauptthemen laut MEDLINE: Acne Vulgaris, Spironolactone. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
Overview of: Santer M, Lawrence M, Renz S, et al. Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial. BMJ. 2023;381:e074349.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Acne VulgarisSpironolactoneFemaleHumansEnglandMineralocorticoid Receptor Antagonists
Stichwörter der Autor:innen
Drug-Related Side Effects and Adverse ReactionsHealth Care Quality, Access, and Evaluation
Substanzen
Mineralocorticoid Receptor AntagonistsSpironolactone
Zitieren
APA
(2023). Spironolactone for acne in women. Drug and Therapeutics Bulletin. https://doi.org/10.1136/dtb.2023.000040
Vancouver
Spironolactone for acne in women. Drug and Therapeutics Bulletin. 2023. doi:10.1136/dtb.2023.000040
BibTeX
@article{euvimed2023,
title = {Spironolactone for acne in women},
journal = {Drug and Therapeutics Bulletin},
year = {2023},
doi = {10.1136/dtb.2023.000040}
}
EUVIMED